Ref ID: 18737
Author:
N. Marti, PhD – Drug Development Project Leader1, A. Gomez-Lopez, PhD – Researcher 2, D. Gargallo-Viola, PhD – Infectious Diseases Manager 1, A. Guglietta, PhD – R&D Director 1, M. Cuenca-Estrella, PhD – Head of the Spanish National Center for Microb
Author address:
1Res. and Dev. Ctr.. Ferrer Internacional SA, Barcelona, Spain, 2Instituto Carlos III, Madrid, Spain.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: Arasertaconazole nitrate is a new antifungal compound for a topical use that has demonstrated a strong in vitro activity against clinically relevant fungal species. In addition to the relevant in vitro activity against yeasts, dermatophytes and opportunistic fungi, arasertaconazole nitrate shows also a moderate anti-inflammatory activity that has the potential to provide clinical benefit in addition to fungus eradication. The clinical development for the Vulvovaginal Candidiasis indication is currently underway. Methods: A total of 299 fluconazole-susceptible (FLC-S) and resistant (FLC-R) Candida spp. clinical isolates were analyzed. Analysis was done according to EUCAST and CLSI FLC breakpoints (susceptible MIC < 2 mg/L, resistant > 4 mg/L). A total of 97 C. albicans (52 FLC-R and 45 FLC-R), 50 C. glabrata (9 FLC-R and 41 FLC-R), 50 C. parapsilosis (44 FLC-R and 6 FLC-R), C. tropicalis (44 FLC-R and 6 FLC-R), and 52 C. krusei were tested. EUCAST reference procedure (document 7.1) was used. C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were included as quality control strains. Results: Results are showed in the table: MIC in mg/L, GM: Geometric mean, MIC50: MIC for 50% of isolates, MIC90: MIC for 90% of isolates, ND: Not done
Conclusions: Arasertaconazole nitrate showed a very potent activity in vitro against both FLU-S and FLU-R Candida isolates. Arasertaconazole was particularly active against C. glabrata strains with MIC values < 0.06 mg/L.
Abstract Number: M-1718
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a